To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Onychomycosis of Toenail Clinical Trial

Official title:

An Open Label Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Hallux Terbinafine Subungual Gel Administered to the Toenail Bed of Patients With Distal-Lateral Subungual Onychomycosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05135910
• Other study ID #: HSG-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 13, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: August 2023
• Source: Hallux, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The key objective is to establish the efficacy, safety, tolerability, and pharmacokinetics of investigational drug Hallux Terbinafine Subungual Gel (HSG) administered over 44 weeks to patients with distal-lateral subungual onychomycosis (DLSO).

Description:

Primary Efficacy: To identify patients achieving Complete Cure in the target toenail at Week 52. Secondary Efficacy: To identify patients that have achieved 1) Clinical Cure, 2) Mycological Cure, and/or 3) Positive Response in the target toenail at Week 52. Plasma Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in a subpopulation of patients over the study period. Nail Pharmacokinetics: To characterize concentrations of terbinafine and major metabolite in distal nail clippings in patients over the study period. HSG Safety and Tolerability Profile: To establish from plasma pharmacokinetics, related adverse events, treatment site reactions, pain, clinically significant changes in medical condition and/or medications, and clinically significant changes in liver function, serum chemistry, urinalysis, and complete blood count over the study period. Subungual Topical Procedure: To establish the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments, the Investigator will record at selected time points 1) nail measurements indicating progressive clearing, 2) the ease and depth of each topical administration, 3) the investigational drug volume administered each treatment, and 4) patient tolerability.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 35
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male and females 18 - 75 years of age inclusive
• Patients with DLSO of at least one great toe
• Patients with DLSO in the target toe confirmed by positive KOH and positive fungal culture for dermatophytes
• Willingness to abstain from pedicures, nail clipping, or application of nail polish or nail cosmetics to their toenails over the study period

Exclusion Criteria:

• History of any significant chronic fungal disease other than onychomycosis or an immunocompromised condition
• Any previous surgery to or abnormalities of the target toe that in the investigator's opinion could prevent the toenail surface area from clearing even if eradication of the DLSO infection is achieved
• Participation in another clinical study of an investigational drug or device within 3 months of screening
• No administration of oral terbinafine or another oral antifungal within 6 months of screening
• No topical antifungal used for onychomycosis or a dermatophyte infection (i.e. tinea pedis) within 3 months of screening
• No uncontrolled diabetes mellitus
• No severe psoriasis or severe atopic dermatitis Other protocol-defined inclusion/exclusion criteria may apply

Related Conditions & MeSH terms

• Onychomycosis
• Onychomycosis of Toenail

Intervention

Drug:
• Hallux Terbinafine Subungual Gel
Hallux Terbinafine Subungual Gel (HSG) administered every 1 to 2 months over 44 weeks.

Locations

Country	Name	City	State
United States	J&S Studies	College Station	Texas
United States	OrthoArizona - East Valley Foot & Ankle Specialists	Mesa	Arizona
United States	Front Range Foot and Ankle Clinic	Parker	Colorado
United States	Oregon Dermatology & Research Center	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Hallux, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Plasma Pharmacokinetics	To characterize plasma concentrations of terbinafine and metabolite from a subset of patients over the study period	Week 52
Other	Nail Pharmacokinetics	To characterize nail concentrations of terbinafine and metabolite from patients over the study period	Week 52
Other	Subungual Topical Procedure	To evaluate the ease and durability of once monthly and once bi-monthly HSG subungual topical treatments to the target toe over 44 weeks. Nail measurements indicating progressive clearing are recorded from an Investigator Global Assessment scale referencing % disease involvement corroborated by nail image analysis. The ease and durability of subungual topical treatment is established using a 5-point Likert Scale. Patient local tolerability is established using a Treatment Site Assessment Scale and Pain Intensity Scale.	Week 44
Other	Patient Global Assessment	To establish each patient's impression of DLSO improvement in their target toe over the study period, patients will reference the following scale (0 = clear of DLSO, 1 = marked improvement of DLSO, 2 = moderately improved DLSO, 3 = slightly improved DLSO, 4 = unchanged, 5 = worse)	Week 52
Other	Safety and Tolerability: Established from patient incidence of Treatment-Emergent Adverse Events	Indicated by the number of patients with treatment-related adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE)	Monitored from screening visit to end of study visit (Week 52)
Other	Safety and Tolerability: Established from clinical laboratory results	Indicated by clinically significant changes in patient liver function, serum chemistry, urinalysis, and complete blood count over the study period	Monitored at selected time points from screening visit to end of study visit (Week 52)
Other	Safety and Tolerability: Established from patient reported medical condition and use of medications	Monitored by assessing clinically significant changes in patient medical condition and/or use of medications over the study period	Monitored from screening visit to end of study visit (Week 52)
Primary	Complete Cure at Week 52 in the Target Toe	Complete Cure is defined as 1) 100% healthy, clear nail, and 2) negative mycology. Healthy, clear nail is absent any disease involvement attributable to DLSO and is determined by Investigator Global Assessment (IGA). Negative mycology is defined as zero visualization of septate hyphae by KOH microscopy (negative KOH) combined with a fungal culture negative for causal dermatophytes (negative fungal culture).	Week 52
Secondary	Clinical Cure in the Target Toe	100% healthy, clear nail	Week 52
Secondary	Mycological Cure in the Target Toe	Negative KOH, negative fungal culture	Week 52
Secondary	Positive Response in the Target Toe	= 80% decrease in disease involvement	Week 52